Member Info for BuenaVista

Opti_mystic, you haven't been here long and I don't know how long you've been using onlne forums, but you need to learn that it is worse than absolutely useless to engage with these trolls whose only purpose here is to stir up trouble. Why worse than absolutely useless? BECAUSE YOU ARE FEEDING THEM and giving them opportunity to come back with more misinformation and shyte. Do that for too long and you'll be filtered like Icecool and Watching are and the only ones taking any notice of your carefully crafted, rational and factual responses will be the trolls - looking for an angle to respond and wind you up. They do not care anything about the facts about Avacta. Thorn/NDN/Eggy is actually paid by Tom Winnifrith to troll Avacta - he was publicly outed a couple of years ago when in his NDN guise.

So Tom Winnifrith has primed his professorial poodle with presentation-related drivel already. Ignore.

This is new. Down at the bottom of slide 9, approximately mid-2025 to mid-2026 which is from the latter part of the TNBC Phase 1b trial (when the results are coming in) through to the early part of the TNBC Phase 2 trial.

https://wsw.com/webcast/leerink38/avctf/2396932 at 08:25

I'm expecting the pub bore to not have a clue about what was in the presentation.

Sound fine here except for the man's "Blah blah, blah. Blah blah blah blah."

Everything from the pub bore is irrelevant.

As someone got this morning's earlier posts deleted, I'll repost:

Here's what another company put in their public announcement about attending the conference: "...will participate in one-on-one investor meetings and provide a corporate update."

It'll be the same for Avacta. The presentation today will be the latest version of the corporate deck, orientated towards their target audience which will be pharma, financial institutions, etc. represented at the conference by people with the requisite scientific knowledge to understand and evaluate licensing/investment opportunities.

Here's what another company put in their public announcement about attending the conference: "...will participate in one-on-one investor meetings and provide a corporate update."

It'll be the same for Avacta. The presentation today will be the latest version of the corporate deck, orientated towards their target audience which will be pharma, financial institutions, etc. represented at the conference by people with the requisite scientific knowledge to understand and evaluate licensing/investment opportunities.

More likely he's given up looking for AVCT in the local phone direcory.

B2H wrote: "Avacta must have moved this [Affimer] IP out of Coris."

For IP, read patents. These will have stayed with - will have continued to be owned and controlled by - the legal entity that is Avacta all the time. Avacta is entitled to use the IP - the legally protected applications described in the patents - in any part of its organisation.

What happens to the patents depends on a number of factors:

- Whether each individual patent covers Tx applications exclusively, Dx applications exclusively, or both Tx and Dx applications, as claimed in the legal scope of each patent. From what CC said, the linking of an Affimer to an antibody, as a technique, is applicable to both and is a technique that Avacta may want to reserve use of (exclusively or non-exclusively).

- Whether whoever purchases Coris even wants to use Affimers. If they do then the applicable patent(s) can be included in the sale either by transfer of ownership or by exclusive or non-exclusive licensing from Avacta. If they don't then Avacta is free to transfer ownership of the applicable patent(s) to an entity that does or to retain ownership and license them out to one or more other entities.

- Whether Avacta wants to retain use now or potentially in the future of any individual patent that covers Dx application, for example diagnostic testing related to the pre|CISION platform. If they do then they can retain the patent and license it out exclusively or non-exclusively to the purchaser of Coris for other uses or they can transfer ownership to the purchaser as part of the Coris sale and license back for their own current and potential future uses.

And it's likely much more complicated and nuanced than that, not least because patent claims, the legally enforceable scope of the application of a patent, vary from narrow, exact, hard definition to nebulous, wide, all-encompassing blah with the former being legally tight and the latter being hardly worth the paper they're written on and a whole spectrum of contention in between that is Lawyer Paradise. Also patents can be related by their similar coverage (claims) as an invention develops.

Yes, but by 3pm 🚀🚀🚀🚀

The presentation will be 40 minutes long, so that's the corporate deck, full repertoire or greatest hits, updated with whatever has been newly announced, as Timster says.

The next presentation starts at 10:40: https://investor.adagene.com/news-releases/news-release-details/adagene-present-leerinks-global-healthcare-conference-2025

Every presentation gets a live broadcast, organised via the Leerink website.🙄

What 'further positive news' from the Leerink conference?

Will Avacta be RNSing it, again, already, just days after Friday's positive news RNS?

Beavis and Butt-Head with their drag queen, Shady Vance.

That yawn was to the pub bore's post, now deleted, not to anyone else!

That yawn was to the pub bore's post, now deleted, not to ES!

Yawn

Yawn

Don't bother arguing with the sea lion. It's endlessly circular.

https://www.michaelnugent.com/wp-content/uploads/2014/11/Wondermark-Sea-Lion.png

Do not ENGAGE.

A new group, which includes the bourse’s former head, is pressuring the London Stock Exchange Group to give up the growth market

A group of investors, brokers and other City executives is set to approach the London Stock Exchange Group with a proposal to acquire AIM, Financial News can reveal, following a tough period for the capital’s junior stock market.

The nine-strong group wants to buy AIM and relaunch the market as the Global Growth Exchange, according to an internal presentation seen by FN.

...

“If London has no appetite to support this approach there are multiple alternative international venues available,” the presentation said.

Reuters first reported the group’s formation and strategy. Full details on its membership and specific goals have not previously been reported.

“We plan to discuss the details of our strategy and approach with LSEG soon,” Prideaux told FN.

He added that the group had received “very widespread support” after consulting with brokers, market-makers, fund managers and other interested parties.

“AIM is not for sale,” LSEG said in a statement. “It is a vital component of our strategy to build a funding continuum that is seamlessly connected so that companies can start, grow, scale and stay in the UK.

“Over the past 30 years, AIM has established its position as the preeminent market for dynamic high-growth businesses supported by a remarkable community of companies, advisors and investors.”

The British government and regulators have pushed for urgent reforms to inject more life into London’s stock market after a dearth of IPOs and heavy outflows from UK stock funds in recent years.

LSEG has recently dismissed suggestions to spin-off its flagship bourse to reflect its transformation into a data and analytics behemoth. Equities now makes up less than 3% of LSEG’s revenue.

AIM, which launched in 1995 and caters to smaller companies, has been battered by a wave of delistings as firms cite liquidity issues.

“With New York effectively closed to IPOs for companies with market capitalisations below $5bn, we believe that there’s an opportunity for the London ecosystem to provide a compelling public alternative to many companies worldwide which are currently using private capital to fund their growth,” Prideaux said.

https://www.fnlondon.com/articles/city-executives-plot-to-buy-aim-e5e7de8f